Hikma Pharmaceuticals strongly objects to the use of its products in capital punishment

London, 15 May 2013 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) notes the press release issued today by the legal action charity Reprieve, regarding the potential use of its injectable phenobarbital for the purpose of capital punishment by the Arkansas Department of Corrections.

Phenobarbital is the world’s most widely used anti-convulsant. Hikma strongly objects to the use of any of its products in capital punishment. The Company is putting in place concrete steps to restrict the supply of its products for unintended uses. It has ceased the direct sale of injectable phenobarbital to US departments of corrections and will work directly with its distribution partners to add restrictions for unintended use to its distribution contracts.

Hikma aims to improve lives by providing patients with access to high quality, affordable medicines. Its medicines are used thousands of times a day to treat illness and save the lives of patients across its markets.

-- ENDS --

Enquiries

FTI Consulting

Ben Atwell/ Julia Phillips/ Matthew Cole +44 (0)20 7831 3113

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa (“MENA”), where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.